ArticleFrontiers in oncology2020
Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Neutrophil-activating Peptide 2 as a Novel Modulator of Fibrin Clot Properties in Patients with Atrial Fibrillation.Translational stroke research · 2024Article
- Management of obstructed colorectal carcinoma in an emergency setting: An update.World journal of gastrointestinal oncology · 2024Review
- Chemokine family significance and prognostic value in colorectal cancer.Frontiers in immunology · 2024Article
- Alterations in Gene Pair Correlations as Potential Diagnostic Markers for Colon Cancer.International journal of molecular sciences · 2022Article
- Screening and identification of biomarkers associated with the immune infiltration of intracerebral hemorrhage.Journal of clinical laboratory analysis · 2022Article
- Identification and validation of key molecules associated with humoral immune modulation in Parkinson's disease based on bioinformatics.Frontiers in immunology · 2022Article
- Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer.Frontiers in immunology · 2022Review
- The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the lack of typical symptoms and signs and sensitive indicators for early diagnosis of obstructive colorectal cancer (OCRC), it is critically needed to find new novel biomarkers to ameliorate the management of OCRC patients. In this study, 472 blood samples were collected and measured by enzyme-linked immunosorbent assay (ELISA) to investigate the value of serum chemokine ligand 7 (CXCL7) in diagnosis and prognosis for OCRC patients. The median concentrations of CXCL7 in non-OCRC and OCRC were both higher than that in controls (both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.